Anxiety Disorders - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Anxiety Disorders - Pipeline Review, H2 2016

Anxiety Disorders - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Anxiety Disorders - Pipeline Review, H2 2016
Published Aug 31, 2016
273 pages — Published Aug 31, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Anxiety Disorders - Pipeline Review, H2 2016, provides an overview of the Anxiety Disorders pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
- The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anxiety Disorders therapeutics and enlists all their major and minor projects
- The report assesses Anxiety Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anxiety Disorders

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication th

  
Source:
Document ID
GMDHC8433IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents214
  List of Tables132
  List of Figures151
Introduction161
  Global Markets Direct Report Coverage161
Anxiety Disorders Overview171
Therapeutics Development182
  Pipeline Products for Anxiety Disorders Overview181
  Pipeline Products for Anxiety Disorders Comparative Analysis191
Anxiety Disorders Therapeutics under Development by Companies204
Anxiety Disorders Therapeutics under Investigation by Universities/Institutes241
Anxiety Disorders Pipeline Products Glance254
  Late Stage Products251
  Clinical Stage Products261
  Early Stage Products271
  Unknown Stage Products281
Anxiety Disorders Products under Development by Companies296
Anxiety Disorders Products under Investigation by Universities/Institutes351
Anxiety Disorders Companies Involved in Therapeutics Development3645
  AbbVie Inc361
  Ache Laboratorios Farmaceuticos S/A371
  Adamed Sp. z o.o.381
  Addex Therapeutics Ltd391
  Amorsa Therapeutics Inc.401
  Avineuro Pharmaceuticals, Inc.411
  Azevan Pharmaceuticals, Inc.421
  Biohaven Pharmaceutical Holding Company Limited431
  Bionomics Limited441
  Boehringer Ingelheim GmbH451
  C4X Discovery Holdings PLC461
  Catalyst Pharmaceuticals, Inc.471
  Corcept Therapeutics Incorporated481
  Edgemont Pharmaceuticals, LLC491
  Eisai Co., Ltd.501
  Eli Lilly and Company511
  Fabre-Kramer Pharmaceuticals, Inc.521
  Gabather AB531
  GlaxoSmithKline Plc541
  GW Pharmaceuticals Plc551
  Humanetics Corporation561
  IntelGenx Corp.571
  Intra-Cellular Therapies, Inc.581
  INVENT Pharmaceuticals, Inc.591
  Lead Discovery Center GmbH601
  Marinus Pharmaceuticals, Inc.611
  Merz Pharma GmbH &Co. KgaA621
  Neuralstem, Inc.631
  Neurelis, Inc.641
  NeuroNascent, Inc.651
  Newron Pharmaceuticals S.p.A.661
  Nippon Chemiphar Co., Ltd.671
  Omeros Corporation681
  Otsuka Holdings Co., Ltd.691
  Pherin Pharmaceuticals, Inc.701
  Pragma Therapeutics711
  Protagenic Therapeutics Inc.721
  Suda Ltd731
  Sumitomo Dainippon Pharma Co., Ltd.741
  Synchroneuron Inc.751
  Tonix Pharmaceuticals Holding Corp.761
  Toray Industries, Inc.771
  Trevena, Inc.781
  TRImaran Pharma, Inc.791
  Turing Pharmaceuticals AG801
Anxiety Disorders Therapeutics Assessment8114
  Assessment by Monotherapy Products811
  Assessment by Target825
  Assessment by Mechanism of Action874
  Assessment by Route of Administration912
  Assessment by Molecule Type932
Drug Profiles95146
  18-MC Drug Profile951
  acamprosate calcium SR Drug Profile962
  ACH-36 Drug Profile981
  ADN-2013 Drug Profile991
  ADX-71441 Drug Profile1004
  ADX-71743 Drug Profile1041
  ADX-88178 Drug Profile1052
  alprazolam Drug Profile1071
  AM-3506 Drug Profile1081
  AVN-0189 Drug Profile1091
  AVN-101 Drug Profile1101
  AVN-628 Drug Profile1111
  BNC-210 Drug Profile1123
  brexpiprazole Drug Profile1156
  CPP-115 Drug Profile1214
  D-473 Drug Profile1251
  Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders Drug Profile1261
  E-2508 Drug Profile1271
  evenamide Drug Profile1283
  FKW-00GA Drug Profile1311
  fluvoxamine maleate Drug Profile1321
  ganaxolone Drug Profile1335
  gepirone hydrochloride ER Drug Profile1382
  GT-001 Drug Profile1401
  HL-9001 Drug Profile1411
  HUF-101 Drug Profile1421
  IC-87201 Drug Profile1431
  INT-0036 Drug Profile1441
  INV-107 Drug Profile1451
  ITI-007 Drug Profile1468
  KDAC-0001 Drug Profile1541
  ketamine hydrochloride Drug Profile1551
  lorazepam Drug Profile1561
  lorazepam ER Drug Profile1571
  LSN-2535717 Drug Profile1581
  LY-2607540 Drug Profile1591
  midazolam hydrochloride Drug Profile1601
  modafinil Drug Profile1611
  nabiximols Drug Profile1627
  NC-2800 Drug Profile1691
  NEO-1940 Drug Profile1701
  NNI-351 Drug Profile1711
  NSI-189 Drug Profile1724
  OMS-527 Drug Profile1762
  Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders Drug Profile1781
  PGT-117 Drug Profile1791
  PH-94B Drug Profile1802
  PN-6047 Drug Profile1821
  PT-00114 Drug Profile1831
  remeglurant Drug Profile1841
  riluzole Drug Profile1853
  Rycal Drug Profile1881
  S-107 Drug Profile1891
  SCT-66 Drug Profile1901
  Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders Drug Profile1911
  Small Molecule to Agonize CB1 Receptor for Inflammatory and Neuropathic Pain Drug Profile1921
  Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders Drug Profile1931
  Small Molecule to Antagonize GPR31 for Anxiety Disorders Drug Profile1941
  Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder Drug Profile1951
  Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis Drug Profile1961
  Small Molecule to Target GPR83 for CNS and Immunological Disorders Drug Profile1971
  Small Molecule to Target Oxytocin for Autism and Anxiety Disorders Drug Profile1981
  Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders Drug Profile1991
  Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders Drug Profile2001
  Small Molecules to Activate Translocator Protein for Anxiety Drug Profile2011
  Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders Drug Profile2021
  Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety Drug Profile2031
  Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder Drug Profile2041
  Small Molecules to Antagonize mGlu2 for Anxiety and Depression Drug Profile2051
  Small Molecules to Antagonize mGluR3 for Anxiety and Depression Drug Profile2061
  Small Molecules to Antagonize mGluR5 for Anxiety Drug Profile2071
  Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders Drug Profile2081
  Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders Drug Profile2091
  Small Molecules to Antagonize TLR-4 for CNS Disorders Drug Profile2101
  Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy Drug Profile2111
  Small Molecules to Modulate Mineralocorticoid Receptor for Anxiety Disorders and Depression Drug Profile2121
  Small Molecules to Target Nicotinic Acetylcholine Receptors for Anxiety Disorder Drug Profile2131
  Small Molecules to Target NMDA Receptor for Obsessive-Compulsive Disorder Drug Profile2141
  Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder Drug Profile2151
  SRX-246 Drug Profile2162
  SRX-251 Drug Profile2182
  STX Drug Profile2201
  Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder Drug Profile2211
  TGFK-08AA Drug Profile2221
  TGSC-01AA(4) Drug Profile2231
  TNX-102 Drug Profile2249
  TRV-250 Drug Profile2331
  UCM-765 Drug Profile2341
  Vaccine for CNS Disorders Drug Profile2351
  VAD-1 Drug Profile2361
  VAD-2 Drug Profile2371
  VU-0431316 Drug Profile2381
  VU-0456810 Drug Profile2391
  ZL-006 Drug Profile2401
Anxiety Disorders Dormant Projects24115
Anxiety Disorders Discontinued Products2565
Anxiety Disorders Product Development Milestones26111
  Featured News &Press Releases2611
    Aug 15, 2016: Tonix Pharmaceuticals Presents Poster on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2016 Military Health System Re2611
    Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder2621
    Jun 24, 2016: Enrolment Completed in BNC210 Generalised Anxiety Disorder Trial2621
    Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases2631
    Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases2631
    Jun 13, 2016: Addex mGluR4 Program Demonstrates Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases2641
    Jun 03, 2016: Tonix Pharmaceuticals to Present at the 2016 BIO International Convention2641
    May 31, 2016: Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the American Society of Clinical Psychopharmacology 2016 Annual Meeting2651
    May 26, 2016: Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting2661
    May 19, 2016: Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)2671
    Mar 09, 2016: Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting2681
    Feb 24, 2016: Biohaven Announces Positive Results from Phase I Study with BHV-02232691
    Jan 13, 2016: Turing Pharmaceuticals Announces Initiation of TUR-002 Clinical Trials2691
    Dec 23, 2015: Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder2701
    Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC2102702
Appendix2722
  Methodology2721
  Coverage2721
  Secondary Research2721
  Primary Research2721
  Expert Panel Validation2721
  Contact Us2721
  Disclaimer2731

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Anxiety Disorders - Pipeline Review, H2 2016" Aug 31, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Anxiety-Disorders-Pipeline-Review-H2-2016-2088-16516>
  
APA:
Global Markets Direct - Market Research. (2016). Anxiety Disorders - Pipeline Review, H2 2016 Aug 31, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Anxiety-Disorders-Pipeline-Review-H2-2016-2088-16516>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.